CHMP5 and viral infectious disease: Although strategies such as monoclonal antibodies against Spike [83], or inhibitors of viral enzymes, are much more advanced in the treatment of viral infections, and specifically of COVID-19, the high mutation rate in Spike proteins [3] must be considered from a long-term perspective.